Cagrilintide is a long-acting synthetic analogue of human amylin, active at the AMY1R, AMY3R and calcitonin receptors. It is used as a reference compound in amylin and calcitonin receptor pharmacology in vitro, and NuVion stocks it in Australia as a 10mg lyophilised vial.
- Long-acting synthetic analogue of human amylin
- Agonist at AMY1R, AMY3R and calcitonin receptors
- Used in receptor binding and second messenger assays
- Supplied lyophilised, purity by RP-HPLC and identity by mass spectrometry
Cagrilintide structure and research use
Cagrilintide is built on the 37 amino acid sequence of human amylin, with amino acid substitutions and a fatty acid side chain added to make it stable in solution and long acting. It is an agonist at the amylin receptors AMY1R and AMY3R and at the calcitonin receptor. In the laboratory it is used as a reference compound in receptor binding and second messenger assays.
Cagrilintide research applications
- Cyclic AMP accumulation in cells co-expressing the calcitonin receptor with a defined RAMP
- Competition binding at AMY1R, AMY2R, AMY3R and the calcitonin receptor to rank subtype affinity
- Thioflavin T fluorescence assays comparing fibril formation with that of native human amylin
- Albumin binding and free fraction measured by equilibrium dialysis or ultrafiltration in serum-containing medium
Cagrilintide key facts
| Type | Synthetic acylated amylin analogue |
|---|---|
| Amino acid count | 37 |
| Parent peptide | Human amylin (IAPP) |
| Modification | C20 fatty diacid side chain via a linker |
| Structural feature | N-terminal disulfide loop, amidated C-terminus |
| Receptors | AMY1R, AMY2R, AMY3R and the calcitonin receptor |
| Vial size | 10mg, lyophilised |
| Purity | 99.94% by RP-HPLC, Janoshik Analytical |
| Analysed | 5 February 2026 |
Research profile: Cagrilintide: structure, mechanism and research use
Independent test: a sample of this product was analysed by Janoshik Analytical on 5 February 2026, purity 99.94% by RP-HPLC. The certificate is shown in the lab band on this page.







